Paratek Pharmaceuticals Inc (PRTK):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Paratek Pharmaceuticals Inc (PRTK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9962
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:45
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Paratek Pharmaceuticals Inc (Paratek) is a biopharmaceutical company that develops and commercializes therapies based on tetracycline chemistry. Omadacycline (antibiotic), the company’s lead product candidate is an aminomethylcycline which acts against gram-negative, gram-positive, and atypical bacteria. It is investigating omadacycline in Phase III for the treatment of infections resistant to antibiotics: acute bacterial skin and skin structure infections (ABSSSI); community acquired bacterial pneumonia (CABP), urinary tract infections (UTI) and other community-acquired bacterial infections. The company is also developing sarecycline an oral, once-daily, antibiotic in Phase III for the treatment of acne and rosacea. Paratek is headquartered in Boston, Massachusetts, the US.

Paratek Pharmaceuticals Inc (PRTK) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Zai Lab Enters into Licensing Agreement with Paratek Pharma 11
Paratek Pharma Enters into Agreement with US Army Medical Research Institute of Infectious Diseases 12
Equity Offering 13
Paratek Pharma Raises USD50 Million in Public Offering of Shares 13
Paratek Pharma Plans to Raise up to USD250 Million in Public Offering of Securities 15
Paratek Pharma Plans to Raise up to USD50 Million in Public Offering 16
Paratek Pharma Raises USD63.53 Million in Public Offering of Shares 17
Paratek Pharma Raises USD76 Million in Public Offering of Shares 19
Paratek Pharma Raises USD93 Million in Private Placement 21
Paratek Pharma Withdraws IPO 23
Debt Offering 24
Paratek Pharma Raises USD140 Million in Private Placement of Notes Due 2024 24
Acquisition 25
Paratek Pharma May Sell Itself 25
Transcept Pharma Acquires Paratek Pharma 27
Paratek Pharmaceuticals Inc – Key Competitors 29
Paratek Pharmaceuticals Inc – Key Employees 30
Paratek Pharmaceuticals Inc – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Strategy And Business Planning 32
Mar 24, 2017: Paratek Pharmaceuticals Opens New Office in King of Prussia 32
Financial Announcements 33
Nov 06, 2018: Paratek Pharmaceuticals reports third quarter 2018 financial results 33
Aug 02, 2018: Paratek Pharmaceuticals announces second quarter 2018 financial results 34
May 09, 2018: Paratek Pharmaceuticals Reports First Quarter 2018 Financial Results 36
Mar 01, 2018: Paratek Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Remains on Track for Commercial Launch by First Quarter 2019 37
Aug 02, 2017: Paratek Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Clinical Update 38
May 04, 2017: Paratek Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Clinical Update 39
Mar 02, 2017: Paratek Pharmaceuticals Reports Full Year and Fourth Quarter 2016 Financial Results and Provides Clinical Update 40
Corporate Communications 41
Apr 13, 2018: Paratek Names Rolf K. Hoffman As Board Director 41
Oct 02, 2017: Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c) 42
Aug 01, 2017: Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 43
Jan 04, 2017: Paratek Pharmaceuticals Announces Promotion of Evan Loh, M.D. to the role of President and Chief Operating Officer 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45

List of Tables
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Paratek Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Zai Lab Enters into Licensing Agreement with Paratek Pharma 11
Paratek Pharma Enters into Agreement with US Army Medical Research Institute of Infectious Diseases 12
Paratek Pharma Raises USD50 Million in Public Offering of Shares 13
Paratek Pharma Plans to Raise up to USD250 Million in Public Offering of Securities 15
Paratek Pharma Plans to Raise up to USD50 Million in Public Offering 16
Paratek Pharma Raises USD63.53 Million in Public Offering of Shares 17
Paratek Pharma Raises USD76 Million in Public Offering of Shares 19
Paratek Pharma Raises USD93 Million in Private Placement 21
Paratek Pharma Withdraws IPO 23
Paratek Pharma Raises USD140 Million in Private Placement of Notes Due 2024 24
Paratek Pharma May Sell Itself 25
Transcept Pharma Acquires Paratek Pharma 27
Paratek Pharmaceuticals Inc, Key Competitors 29
Paratek Pharmaceuticals Inc, Key Employees 30
Paratek Pharmaceuticals Inc, Other Locations 31
Paratek Pharmaceuticals Inc, Subsidiaries 31

List of Figures
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Paratek Pharmaceuticals Inc (PRTK):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Srei Infrastructure Finance Ltd:企業の戦略・SWOT・財務分析
    Srei Infrastructure Finance Ltd - Strategy, SWOT and Corporate Finance Report Summary Srei Infrastructure Finance Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • GulfMark Offshore Inc (GLF):石油・ガス:M&Aディール及び事業提携情報
    Summary GulfMark Offshore Inc (GulfMark Offshore), formerly New GulfMark Offshore Inc is an oil and gas company that offers oil and gas, and marine transportation services. The company owns, operates, and manages fleet of vessels offering marine specialty services to offshore oil and natural gas dri …
  • Fifth Third Bancorp:企業のM&A・事業提携・投資動向
    Fifth Third Bancorp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Fifth Third Bancorp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Agile Therapeutics Inc (AGRX):医療機器:M&Aディール及び事業提携情報
    Summary Agile Therapeutics Inc (Agile) is a healthcare company that develops and commercializes prescription contraceptive products for women. The company provides contraceptive patch containing the active ingredients levonorgestrel and ethinyl estradiol and progestin-only birth control patch. Its p …
  • Banyan Biomarkers Inc:企業の製品パイプライン分析2018
    Summary Banyan Biomarkers Inc (Banyan Biomarkers) is a medical technology company that commercializes vitro diagnostic tests for the detection of traumatic brain injury and neurological diseases. The company’s product pipeline includes biomarkers for depression, hypoxic ischemic encephalopathy, neur …
  • RainDance Technologies Inc:医療機器:M&Aディール及び事業提携情報
    Summary RainDance Technologies Inc (RDT), a subsidiary of Bio-Rad Laboratories Inc is a developer of genomic tools for non-invasive liquid biopsy applications. The company’s products include RainDrop Plus, a digital PCR system that provides picoliter droplets for multiplex detection of HIV and DNA; …
  • Aerie Pharmaceuticals Inc (AERI):企業の財務・戦略的SWOT分析
    Aerie Pharmaceuticals Inc (AERI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Empresaria Group plc (EMR):企業の財務・戦略的SWOT分析
    Empresaria Group plc (EMR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • WEC Energy Group:企業の戦略・SWOT・財務情報
    WEC Energy Group - Strategy, SWOT and Corporate Finance Report Summary WEC Energy Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • De La Rue Plc (DLAR):企業の財務・戦略的SWOT分析
    De La Rue Plc (DLAR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Sysmex Corp (6869):企業の財務・戦略的SWOT分析
    Sysmex Corp (6869) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Havells India Ltd (HAVELLS):企業の財務・戦略的SWOT分析
    Havells India Ltd (HAVELLS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • MAXrad SOFTware (India) Pvt. Ltd.:企業の戦略・SWOT・財務情報
    MAXrad SOFTware (India) Pvt. Ltd. - Strategy, SWOT and Corporate Finance Report Summary MAXrad SOFTware (India) Pvt. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Power Grid Corporation of India Ltd (POWERGRID EQ):企業の財務・戦略的SWOT分析
    Power Grid Corporation of India Ltd (POWERGRID EQ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • Tredegar Corp (TG):企業の財務・戦略的SWOT分析
    Tredegar Corp (TG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • BioCryst Pharmaceuticals Inc (BCRX):企業の財務・戦略的SWOT分析
    BioCryst Pharmaceuticals Inc (BCRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Custodian & Allied Plc:企業の戦略・SWOT・財務分析
    Custodian & Allied Plc - Strategy, SWOT and Corporate Finance Report Summary Custodian & Allied Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Dah Chong Hong Holdings Ltd (1828):企業の財務・戦略的SWOT分析
    Dah Chong Hong Holdings Ltd (1828) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Supreme Pharmaceuticals Inc (SL)-製薬・医療分野:企業M&A・提携分析
    Summary Supreme Pharmaceuticals Inc (Supreme Pharmaceuticals), formerly Supreme Resources Ltd is a medial products production and distributing company. The company's products include medical marijuana, sun grown marijuana and others. It offers services such as production, exploration, trading, culti …
  • Luxembourg Institute of Health:製薬・医療:M&Aディール及び事業提携情報
    Summary Luxembourg Institute of Health (LIH), formerly Centre de Recherche Public de la Sante is a biomedical research organisation that offers pre-clinical and clinical research in the areas of biomedicine and healthcare. The organization offers research under various departments such as infection …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆